Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived

NCT03469297 | Completed Results DMC FDA Device

• 1 other identifier: 4039
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 3

Brief Summary

This is a prospective, non-randomized, single-arm early feasibility study to assess the safety and feasibility of lowering intraocular pressure with the Brown Glaucoma Implant. A total of up to 10 subjects will be enrolled at three centers. Subjects will be followed for 24 months, with the primary assessments completed 6 months after implant.

Conditions

Glaucoma

Outcome Measures

Primary Outcomes (2)

• Overall Responder Rate

  Responder rate defined as achieving at least 20% reduction from baseline in intra-ocular pressure (IOP)

  6 Months

• Adverse Event Rate

  Rate of all AEs

  6 Months

Secondary Outcomes (3)

• Mean Change From Baseline in IOP

  Baseline, 6 Months

• Alternative Responder Rate

  6 Months

• Change in IOP-lowering Medications

  Baseline, 6 Months

Study Arms (1)

Brown Glaucoma Implant

EXPERIMENTAL

Device: Brown Glaucoma Implant

Interventions

Brown Glaucoma Implant DEVICE

The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.

Brown Glaucoma Implant

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 22 years and older.
• Best corrected visual acuity of 20/400 or worse.in the study eye.
• Fellow eye with visually acuity of 20/200 or better and the visual field no worse than the study eye. If the study eye has no light perception, the fellow eye may have no light perception or better.
• Intraocular pressure in the study eye greater than or equal to 21 mmHg and less than or equal to 50 mmHg.
• Primary open-angle glaucoma (confirmed by gonioscopy).
• Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: (1) Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; (2) Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or (3) Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
• Humphrey Visual Field (HVF) demonstrating visual field defects consistent with glaucomatous optic nerve damage.
• At least two contiguous clock hours of intact conjunctiva near the limbus between clock hours of 9:00 and 03:00 in the study eye.
• Adequate space in the anterior chamber of the study eye sufficient to support implant with the BGI, defined as two contiguous clock hours of scleral spur visualization via goinioscopy, without compression, in the superior 180 degrees of the anterior angle.
• Able and willing to comply with protocol requirements.
• Able to understand and sign the Informed Consent form.

You may not qualify if:

• Active Neovascular Glaucoma in the study eye.
• Pigmentary Glaucoma in the study eye.
• Pseudoexfoliative Glaucoma in the study eye.
• Corneal conditions in the study eye that may inhibit normal incisional healing (e.g. Fuch's dystrophy) or impair visualization of the implant inside the anterior chamber.
• Anticipated need for ocular surgery within one year in the study eye.
• Requirement of a combined glaucoma procedure in the study eye.
• Contact lens use in the study eye.
• Clinically significant inflammation or infection in the study eye within 60 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) or any systemic infection. For purposes of this study, clinically significant is considered any such condition requiring prescription therapy.
• Other clinical conditions:
• Poorly controlled diabetes (Type I or Type II) as determined by HbA1c \>8.
• Cancer requiring treatment during the duration of the study.
• Any drugs (e.g.: immunosuppressive drugs) or co-morbidity that might inhibit wound healing.
• Participation in any other clinical trial during participation in this trial.
• Life expectancy \<1 year.
• If both eyes of a prospective trial participant are eligible, only the eye with the highest intraocular pressure will be selected for implant.

Sponsors & Collaborators

• MicroOptx: lead

Study Sites (3)

Minnesota Eye Consultants

Bloomington, Minnesota, 55431, United States

Location

iWorks Laser and Vision Center

Dayton, Ohio, 45405, United States

Location

Glaucoma Associates of Texas

Dallas, Texas, 75231, United States

Location

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Limitations and Caveats

Approximately 2 weeks after the initial implant, one subject (02-03) had the first BAM device explanted due to device channel blockage and elevated intra-ocular pressure. A second BAM device was implanted immediately after the explant procedure.

Results Point of Contact

• Title: VP of Clinical
• Organization: MicroOptx

info@microoptx.com

888-591-2784

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2018
• First Posted: March 19, 2018
• Study Start: May 1, 2018
• Primary Completion: March 26, 2020
• Study Completion: September 20, 2021
• Last Updated: December 28, 2022
• Results First Posted: December 5, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)